Menopause Management--Getting Clinical Care Back on Track.

@article{Manson2016MenopauseMC,
  title={Menopause Management--Getting Clinical Care Back on Track.},
  author={JoAnn E. Manson and Andrew M. Kaunitz},
  journal={The New England journal of medicine},
  year={2016},
  volume={374 9},
  pages={
          803-6
        }
}
Use of systemic hormone therapy has decreased dramatically among U.S. women since the Women's Health Initiative results were published. But those results are being misapplied to treatment decisions for women in their 40s and 50s who have distressing vasomotor symptoms. 
View on PubMed
doi.org
160 Citations
Highly Influential Citations
6
Background Citations
42
Methods Citations
4
Results Citations
3

160 Citations

Integrative Women's Health.

Hormone Therapy for Menopausal Women in the Primary Care Setting

Women’s Health Initiative and menopausal hormone management

  • S. Chan
  • Medicine
    Hong Kong Journal of Gynaecology, Obstetrics and Midwifery
  • 2021
Risks and benefits of menopausal hormone therapy in terms of coronary heart disease, breast cancer, stroke, pulmonary embolism and venous thromboembolism, colorectal cancer, endometrial cancer, and hip fractures are discussed.

Hormone Replacement Therapy in Menopause

The prevalence of vasomotor and vaginal symptoms in women who experience natural menopause is reported to be 50–82% and the occurrence of symptoms increases during perimenopause and usually peaks at the actual onset ofMenopause.

A call to increase the use of hormone therapy to prevent disease in symptomatic postmenopausal women.

Clinical guidelines for menopause hormone therapy recommend HT for symptom control and disease prevention for symptomatic women under age 50, but since the Women’s Health Initiative (WHI) report in 2002 the decline in use has been precipitous.

The Menopause Management Vacuum.

The menopause management gaps are outlined and a multipronged approach to close these gaps and improve the care of midlife women is discussed.

Menopausal Hormone Therapy to Prevent Chronic Conditions

Findings from randomized clinical trials, as well as preclinical, clinical, and epidemiologic studies, clarify the favorable benefit-risk profile for MHT use by recently menopausal women with bothersome vasomotor and related menopausal symptoms.

Menopause: Hormones, Lifestyle, and Optimizing Aging.

  • M. J. Minkin
  • Medicine
    Obstetrics and gynecology clinics of North America
  • 2019

Women harmed by vaginal laser for treatment of GSM—the latest casualties of fear and confusion surrounding hormone therapy

Genitourinary syndrome of menopause (GSM) represents a highly prevalent condition in menopausal women which impairs quality of life. Unless treated, GSM is chronic and progressive.

Making choices at menopause.

The aim of this article is to review the key components of the assessment of women who are perimenopausal or menopausal, and to discuss the benefits and risks of hormonal and non-hormonal treatments, thereby assisting clinicians to appropriately manage these women.
...

6 References

Competency in menopause management: whither goest the internist?

It is proposed that the multidimensional expertise that characterizes the internist may provide the most comprehensive approach to menopause management and for this need, a set of core competencies must be attained.

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.

Most risks and benefits dissipated postintervention, although some elevation in breast cancer risk persisted during cumulative follow-up and the 2 WHI hormone therapy trials do not support use of this therapy.

Use of compounded hormone therapy in the United States: report of The North American Menopause Society Survey

This survey indicates substantial use of C-HT across the country and the possibility of higher rates of endometrial side effects with such products and a need for standardized data collection on the extent of use of compounded hormones and their potential risks.

Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline.

Menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and other symptoms of the climacteric and benefits may exceed risks for the majority of symptomatic postmenopausal women who are under age 60 or under 10 years since the onset of menopause.

Needs and priorities in women's health training: perspectives from an internal medicine residency program.

Key gaps remain in WH training and the importance of reinforcing WH training with hands-on management opportunities is emphasized, as well as understanding institution-specific strengths and weaknesses may help guide the development of targeted initiatives.

Society Survey

  • 2015